- Conditions
- Dengue Fever
- Interventions
- 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
- Biological · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 296
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Cancer
- Interventions
- girentuximab, placebo
- Biological · Other
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 39
- States / cities
- Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
- Conditions
- Streptococcus Pneumoniae
- Interventions
- PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 84 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- lapatinib ditosylate, letrozole, placebo
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Alzheimer's Disease
- Interventions
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS)
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Erlotinib, Placebo
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 122 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Everolimus, Everolimus Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 34
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Belzutifan, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
- Conditions
- COVID-19
- Interventions
- VXA-CoV2-1.1-S, Placebo Tablets
- Drug · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 15
- States / cities
- Tampa, Florida • Atlanta, Georgia • Augusta, Georgia + 11 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- MEDI7510, IIV, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 1,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 30
- States / cities
- Sacramento, California • San Francisco, California • Aurora, Colorado + 27 more
- Conditions
- Influenza, Human
- Interventions
- NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,375 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
- Conditions
- Zika Virus Infection
- Interventions
- Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Coronavirus (SARS-CoV)
- Interventions
- Aluminum hydroxide, Placebo, SARS-CoV
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Selumetinib, Placebo, Radioactive Iodine Therapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Prostate Cancer
- Interventions
- tarenflurbil, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
- Conditions
- HIV Infection
- Interventions
- PENNVAX-B, GENEVAX IL-12-4532, PLACEBO, IL-15 adjuvant
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Genital Herpes, HSV-2 Infection
- Interventions
- GEN-003, Matrix-M2, 0.9% normal saline
- Biological · Other
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Pain
- Interventions
- nicotine patch, placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
- Conditions
- Dengue
- Interventions
- TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 20 Years to 49 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Silver Spring, Maryland
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Influenza
- Interventions
- AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
- Drug · Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more